gamma-aminobutyric acid has been researched along with Hepatic Encephalopathy in 140 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 8.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| "To investigate the metabolic changes in type C hepatic encephalopathy (CHE) rats after reducing manganese (Mn) intake." | 8.12 | Metabolic changes of the reduction of manganese intake in the hepatic encephalopathy rat: NMR- and MS-based metabolomics study. ( Li, Y; Lu, J; Qiang, J; Yang, X; Zhang, C, 2022) |
| " Sulforaphane could be a new therapeutic approach to improve cognitive and motor function in hyperammonemia, hepatic encephalopathy, and other pathologies associated with neuroinflammation by promoting microglia differentiation from M1 to M2." | 7.83 | Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016) |
| "High affinity [3H]gamma-aminobutyric acid (GABA) and [3H]L-glutamate uptake were determined in synaptosomes prepared from the cerebral cortex of dogs with congenital hepatic encephalopathy and control dogs." | 7.69 | L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. ( Johnston, GA; Maddison, JE; Watson, WE, 1995) |
| "The release of newly loaded [3H]GABA was studied in slices of different brain regions derived from rats in which acute hepatic encephalopathy (HE) was induced with a hepatotoxin thioacetamide." | 7.68 | Enhanced GABA release in cerebral cortical slices derived from rats with thioacetamide-induced hepatic encephalopathy. ( Albrecht, J; Oja, SS; Saransaari, P; Wysmyk, U, 1992) |
| "The plasma gamma-aminobutyric acid (GABA) concentration was measured by a radio-receptor assay in rat model of hepatic encephalopathy due to fulminant hepatic failure (FHF) induced by intraperitoneal injection of D-galactosamine (GalN)." | 7.68 | [Study on variation of plasma gamma-aminobutyric acid concentration in rat model of hepatic encephalopathy due to fulminant hepatic failure]. ( He, X; Luan, Y, 1992) |
| "Crude (P2) synaptosomes derived from rats with acute hepatic encephalopathy (HE) induced with thioacetamide showed a slightly increased uptake of radiolabeled arginine (ARG) and a 2." | 7.68 | Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response? ( Albrecht, J; Hilgier, W; Rafałowska, U, 1990) |
| " Gas-liquid chromatography and a radioreceptor assay were used to measure plasma gamma-aminobutyric acid (GABA) in patients with liver disease and hepatic encephalopathy." | 7.67 | Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy. ( Leek, J; Levy, LJ; Losowsky, MS, 1987) |
| "Blood-brain barrier permeability to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), to sucrose and to sodium was studied in rats with galactosamine-induced liver damage and hepatic encephalopathy by means of an arterial integral uptake technique." | 7.67 | Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. ( Knudsen, GM; Paulson, OB; Poulsen, HE, 1988) |
| "The progressive course of hepatic encephalopathy developing in rats after massive hepatic ischemia due to hepatic artery ligation within 48 hr of a portacaval shunt was not altered by the injection of a benzodiazepine antagonist, CGS 8216, in a dose that was sufficient to reverse diazepam-induced coma quickly." | 7.67 | A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. ( Ebner, J; Ferenci, P; Rzepczynski, D; Zieve, L; Zimmermann, C, 1987) |
| "Brain gamma-aminobutyric acid (GABA) receptor density, affinity, and function, and plasma GABA-like activity were determined in rats with acute hepatic encephalopathy induced by an intraperitoneal injection of thioacetamide." | 7.67 | Brain gamma-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma-aminobutyric acid-like activity. ( Dodd, PR; Farrell, GC; Johnston, GA; Maddison, JE, 1987) |
| " The neosynthesis of this amino acid from glucose was also studied in two experimental models of hepatic encephalopathy: (1) rats receiving large amounts of ammonium acetate (i." | 7.66 | The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. ( Cortesini, C; Lombardi, G; Moneti, G; Moroni, F, 1983) |
| " It is now reported that membrane preparations from rats with mild galactosamine-induced hepatic encephalopathy show an increase in the number of low- and high-affinity gamma-aminobutyric acid binding sites, whereas those from rats with severe encephalopathy show only high-affinity binding sites." | 7.66 | Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. ( Baraldi, M; Zeneroli, ZL, 1982) |
| "Kinetic studies of [3H]gamma-aminobutyric acid ([3H]GABA) after an intravenous injection were performed in normal rats and in rats with severe degree of hepatic encephalopathy due to fulminant hepatic failure induced by galactosamine." | 7.66 | Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats. ( Baraldi, M; Iuliano, E; Racagni, G; Zeneroli, ML, 1982) |
| "Sulforaphane promotes polarization of microglia from the M1 to the M2 phenotype, reducing IL-1b and increasing IL-4, IL-10, Arg1, and YM-1 in the cerebellum." | 5.43 | Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016) |
| "In rats with hepatic encephalopathy, the concentrations of GABA, glutamate and taurine were decreased in the cerebral cortex, the hippocampus and the striatum, whereas those of aspartate and glycine were unchanged or increased." | 5.28 | Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission. ( Ebner, J; Ferenci, P; Hörtnagl, H; Lassmann, H; Pifl, C; Roth, E; Yurdaydin, C; Zimmermann, C, 1989) |
| "in galactosamine-treated animals." | 5.27 | Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. ( Knudsen, GM; Paulson, OB; Poulsen, HE, 1988) |
| "The progressive course of hepatic encephalopathy developing in rats after massive hepatic ischemia due to hepatic artery ligation within 48 hr of a portacaval shunt was not altered by the injection of a benzodiazepine antagonist, CGS 8216, in a dose that was sufficient to reverse diazepam-induced coma quickly." | 5.27 | A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. ( Ebner, J; Ferenci, P; Rzepczynski, D; Zieve, L; Zimmermann, C, 1987) |
| "Thus, hepatic encephalopathy appears to involve partial degeneration of the gamma-aminobutyric acid-containing presynaptic nerve terminals." | 5.26 | Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. ( Baraldi, M; Zeneroli, ZL, 1982) |
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 4.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| "To investigate the metabolic changes in type C hepatic encephalopathy (CHE) rats after reducing manganese (Mn) intake." | 4.12 | Metabolic changes of the reduction of manganese intake in the hepatic encephalopathy rat: NMR- and MS-based metabolomics study. ( Li, Y; Lu, J; Qiang, J; Yang, X; Zhang, C, 2022) |
| " Sulforaphane could be a new therapeutic approach to improve cognitive and motor function in hyperammonemia, hepatic encephalopathy, and other pathologies associated with neuroinflammation by promoting microglia differentiation from M1 to M2." | 3.83 | Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016) |
| "The combined level of gamma-aminobutyric acid (GABA) plus homocarnosine was lower in the alcohol-dependent and hepatic encephalopathy patients than in the healthy subjects." | 3.70 | Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. ( Behar, KL; Charney, DS; Delaney, R; Hooten, M; Krystal, JH; Navarro, V; Petersen, KF; Petrakis, IL; Petroff, OA; Rothman, DL; Shulman, GI, 1999) |
| "High affinity [3H]gamma-aminobutyric acid (GABA) and [3H]L-glutamate uptake were determined in synaptosomes prepared from the cerebral cortex of dogs with congenital hepatic encephalopathy and control dogs." | 3.69 | L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. ( Johnston, GA; Maddison, JE; Watson, WE, 1995) |
| "Increased gamma-aminobutyric acid (GABA) neurotransmission has been implicated in the pathogenesis of hepatic encephalopathy." | 3.68 | Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. ( Basile, AS; Harrison, PM; Hughes, RD; Jones, EA; Murata, Y; Pannell, L; Skolnick, P; Williams, R, 1991) |
| "The release of newly loaded [3H]GABA was studied in slices of different brain regions derived from rats in which acute hepatic encephalopathy (HE) was induced with a hepatotoxin thioacetamide." | 3.68 | Enhanced GABA release in cerebral cortical slices derived from rats with thioacetamide-induced hepatic encephalopathy. ( Albrecht, J; Oja, SS; Saransaari, P; Wysmyk, U, 1992) |
| "The plasma gamma-aminobutyric acid (GABA) concentration was measured by a radio-receptor assay in rat model of hepatic encephalopathy due to fulminant hepatic failure (FHF) induced by intraperitoneal injection of D-galactosamine (GalN)." | 3.68 | [Study on variation of plasma gamma-aminobutyric acid concentration in rat model of hepatic encephalopathy due to fulminant hepatic failure]. ( He, X; Luan, Y, 1992) |
| "We repeatedly measured blood-brain barrier passage of phenylalanine, leucine, glucose and GABA in nine patients with hepatic encephalopathy using the intravenous double-indicator technique." | 3.68 | Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. ( Almdal, T; Knudsen, GM; Paulson, OB; Schmidt, J; Vilstrup, H, 1993) |
| "The binding of [3H]GABA to GABAA and GABAB binding sites was measured in cerebral cortical membranes derived from control rats and rats with acute hepatic encephalopathy (HE) induced with a hepatotoxin, thioacetamide." | 3.68 | Loss of GABAB binding sites in the cerebral cortex of rats with acute hepatic encephalopathy. ( Albrecht, J; Oja, SS; Saransaari, P; Wysmyk, U, 1993) |
| "Crude (P2) synaptosomes derived from rats with acute hepatic encephalopathy (HE) induced with thioacetamide showed a slightly increased uptake of radiolabeled arginine (ARG) and a 2." | 3.68 | Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response? ( Albrecht, J; Hilgier, W; Rafałowska, U, 1990) |
| "Brain concentrations of substances inhibiting the binding of [3H]flumazenil to its receptors are increased in some patients with hepatic encephalopathy due to fulminant hepatic failure." | 3.68 | Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. ( Basile, AS; Harrison, PM; Hughes, RD; Jones, EA; Murata, Y; Pannell, L; Skolnick, P; Williams, R, 1991) |
| "The progressive course of hepatic encephalopathy developing in rats after massive hepatic ischemia due to hepatic artery ligation within 48 hr of a portacaval shunt was not altered by the injection of a benzodiazepine antagonist, CGS 8216, in a dose that was sufficient to reverse diazepam-induced coma quickly." | 3.67 | A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. ( Ebner, J; Ferenci, P; Rzepczynski, D; Zieve, L; Zimmermann, C, 1987) |
| "Recently it has been suggested that gamma-aminobutyric acid (GABA), a potent inhibitory neurotransmitter, may be involved in the pathogenesis of hepatic encephalopathy." | 3.67 | The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes. ( Minuk, GY; Sarjeant, EJ, 1988) |
| "Blood-brain barrier permeability to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), to sucrose and to sodium was studied in rats with galactosamine-induced liver damage and hepatic encephalopathy by means of an arterial integral uptake technique." | 3.67 | Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. ( Knudsen, GM; Paulson, OB; Poulsen, HE, 1988) |
| " Gas-liquid chromatography and a radioreceptor assay were used to measure plasma gamma-aminobutyric acid (GABA) in patients with liver disease and hepatic encephalopathy." | 3.67 | Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy. ( Leek, J; Levy, LJ; Losowsky, MS, 1987) |
| "It has been hypothesized that gamma-aminobutyric acid (GABA), the principle inhibitory neurotransmitter of the mammalian brain, contributes to the neural inhibition of hepatic encephalopathy." | 3.67 | gamma-Aminobutyric acid plasma levels and brain binding in Eck fistula dogs. ( Hodgson, PE; Schafer, DF; Schafer, GJ; Thompson, JS, 1985) |
| "Elevated serum levels of gamma-aminobutyric acid (GABA), a potent inhibitory neurotransmitter, have recently been implicated in the pathogenesis of hepatic encephalopathy." | 3.67 | Elevated serum gamma-aminobutyric acid levels in children with Reye's syndrome. ( Buchan, K; Minuk, GY; Sarjeant, EJ, 1985) |
| "Brain gamma-aminobutyric acid (GABA) receptor density, affinity, and function, and plasma GABA-like activity were determined in rats with acute hepatic encephalopathy induced by an intraperitoneal injection of thioacetamide." | 3.67 | Brain gamma-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma-aminobutyric acid-like activity. ( Dodd, PR; Farrell, GC; Johnston, GA; Maddison, JE, 1987) |
| "If the gamma-aminobutyric acid (GABA) inhibitory neurotransmitter system plays an important role in the mediation of hepatic encephalopathy (HE) in man, changes in the status of receptors for GABA in the brain may occur in patients with HE." | 3.67 | Changes in cerebral receptors for gamma aminobutyric acid in patients with hepatic encephalopathy. ( Ferenci, P; Jellinger, K; Jones, EA; Riederer, P; Schafer, DF, 1988) |
| "Kinetic studies of [3H]gamma-aminobutyric acid ([3H]GABA) after an intravenous injection were performed in normal rats and in rats with severe degree of hepatic encephalopathy due to fulminant hepatic failure induced by galactosamine." | 3.66 | Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats. ( Baraldi, M; Iuliano, E; Racagni, G; Zeneroli, ML, 1982) |
| "The concentrations of catecholamines, serotonin, histamine and GABA as well as some of their precursors and metabolites were measured in the CSF and the serum of human patients at different grades of hepatic encephalopathy." | 3.66 | Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy. ( Borg, J; Imler, M; Mack, G; Marescaux, C; Schlienger, JL; Warter, JM, 1982) |
| "Serum levels of GABA (gamma-aminobutyric acid)-like activity were measured by a radioreceptor assay in 22 healthy subjects and 170 patients with liver diseases." | 3.66 | Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. ( Ferenci, P; Hoofnagle, JH; Jones, EA; Kleinberger, G; Schafer, DF, 1983) |
| " The neosynthesis of this amino acid from glucose was also studied in two experimental models of hepatic encephalopathy: (1) rats receiving large amounts of ammonium acetate (i." | 3.66 | The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. ( Cortesini, C; Lombardi, G; Moneti, G; Moroni, F, 1983) |
| " It is now reported that membrane preparations from rats with mild galactosamine-induced hepatic encephalopathy show an increase in the number of low- and high-affinity gamma-aminobutyric acid binding sites, whereas those from rats with severe encephalopathy show only high-affinity binding sites." | 3.66 | Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. ( Baraldi, M; Zeneroli, ZL, 1982) |
| "Neuropathology of hepatic encephalopathy (HE) in cirrhosis is primarily astroglial in nature characterized by Alzheimer type 2 astrocytosis together with activation of microglia indicative of neuroinflammation." | 2.61 | Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. ( Butterworth, RF, 2019) |
| "The cognitive and motor alterations in hepatic encephalopathy (HE) are the final result of altered neurotransmission and communication between neurons in neuronal networks and circuits." | 2.52 | Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy. ( Agusti, A; Balzano, T; Belghiti, M; Cabrera-Pastor, A; Dadsetan, S; Felipo, V; Garcia-Garcia, R; Gomez-Gimenez, B; Hernandez-Rabaza, V; Llansola, M; Malaguarnera, M; Montoliu, C; Taoro, L, 2015) |
| "Hyperammonemia is necessary for development of the cerebral complications to liver disease including hepatic encephalopathy and cerebral edema but the mechanisms are unclear." | 2.50 | Cerebral effects of ammonia in liver disease: current hypotheses. ( Ott, P; Vilstrup, H, 2014) |
| "Hepatic encephalopathy is a neuropsychiatric complication of liver cirrhosis the symptoms of which may vary from imperceptible to severe, invaliding, and even lethal." | 2.50 | Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy. ( Liakina, V; Savlan, I; Valantinas, J, 2014) |
| "Minimal hepatic encephalopathy is also important because of its tendency to impair patients' cognitive functions and quality of life." | 2.50 | Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy. ( Liakina, V; Savlan, I; Valantinas, J, 2014) |
| "Hepatic encephalopathy is a medical phenomenon that is described as a neuropsychiatric manifestation of chronic or acute liver disease that is characterized by psychomotor, intellectual and cognitive abnormalities with emotional/affective and behavioral disturbances." | 2.49 | Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. ( Cichoż-Lach, H; Michalak, A, 2013) |
| "While overt hepatic encephalopathy can be diagnosed using bedside clinical tests, minimal hepatic encephalopathy is clinically invisible and requires psychometric testing to diagnose." | 2.48 | Hepatic encephalopathy. ( Cobbold, JF; McPhail, MJ; Patel, D; Taylor-Robinson, SD, 2012) |
| "Hepatic encephalopathy has a substantial societal burden because of its impact on survival, quality of life and daily functioning, including an impaired ability to drive, leaving patients especially vulnerable to road traffic accidents (Ferenci et al, 2002; Prakash and Mullen, 2010)." | 2.48 | Hepatic encephalopathy. ( Cobbold, JF; McPhail, MJ; Patel, D; Taylor-Robinson, SD, 2012) |
| "Hepatic encephalopathy is a serious and potentially fatal complication of both acute and chronic liver disease, arising as a result of hepatocellular failure, cirrhosis and/or portal-systemic shunting (Ferenci et al, 2002)." | 2.48 | Hepatic encephalopathy. ( Cobbold, JF; McPhail, MJ; Patel, D; Taylor-Robinson, SD, 2012) |
| "Patients with hepatic encephalopathy (HE) may present different neurological alterations including impaired cognitive function and altered motor activity and coordination." | 2.45 | Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. ( Agustí, A; Boix, J; Cauli, O; El Mlili, N; Felipo, V; Llansola, M; Monfort, P; Montoliu, C; Piedrafita, B; Rodrigo, R, 2009) |
| "Hyperammonemia is a main contributor to the alterations in neurotransmission and in neurological functions in HE." | 2.45 | Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. ( Agustí, A; Boix, J; Cauli, O; El Mlili, N; Felipo, V; Llansola, M; Monfort, P; Montoliu, C; Piedrafita, B; Rodrigo, R, 2009) |
| "Pathogenesis of hepatic encephalopathy has not been fully revealed and there are many factors which may affect its development." | 2.42 | [Ammonia and GABA-ergic neurotransmission in pathogenesis of hepatic encephalopathy]. ( Helewski, K; Konecki, J; Kowalczyk-Ziomek, G, 2003) |
| "Hepatic encephalopathy is frequently, though not always, accompanied by elevated blood ammonia level." | 2.42 | [Ammonia and GABA-ergic neurotransmission in pathogenesis of hepatic encephalopathy]. ( Helewski, K; Konecki, J; Kowalczyk-Ziomek, G, 2003) |
| "There appears to be a consensus that hepatic encephalopathy (HE) is a metabolic encephalopathy with a multifactorial pathogenesis." | 2.41 | Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. ( Jones, EA, 2002) |
| "Hepatic encephalopathy is considered to be a reversible metabolic encephalopathy, which occurs as a complication of hepatocellular failure and is associated with increased portal-systemic shunting of gut-derived nitrogenous compounds." | 2.41 | Pathogenesis of hepatic encephalopathy. ( Jones, EA, 2000) |
| "Taurine (Tau) is an amino acid that is thought to mimic GABA function because of its agonistic properties towards GABA(A) receptors, and to contribute to neuroprotection and osmoregulation." | 2.41 | The role of inhibitory amino acidergic neurotransmission in hepatic encephalopathy: a critical overview. ( Albrecht, J; Zielińska, M, 2002) |
| "The treatment of hepatic encephalopathy is predominantly an empirical approach because the process pathogenesis of this syndrome is uncertain." | 2.39 | Treatment of hepatic encephalopathy in patients with cirrhosis of the liver. ( Ferenci, P, 1996) |
| "Alcoholic cirrhosis is frequently associated with episodes of portal-systemic encephalopathy (PSE)." | 2.38 | "Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. ( Butterworth, RF; Lavoie, J, 1993) |
| "Hepatic encephalopathy is a neuropsyquiatric syndrome associated to multifactorial metabolic disruptions." | 2.38 | [Pathogenesis of portal systemic encephalopathy]. ( Barragán, RF; García Compeán, D; Valadez Castillo, R, 1990) |
| "Gamma-aminobutyric acid (GABA) is a potent amino acid neurotransmitter with various physiologic effects throughout the body." | 2.38 | Gamma-aminobutyric acid and the liver. ( Minuk, GY, 1993) |
| "A new approach to pathogenetic study of hepatic encephalopathy was recently undertaken in order to identify the neurological alterations of the brain which characterize the coma." | 2.37 | Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. ( Zeneroli, ML, 1985) |
| "In patients with hepatic encephalopathy, GABA+ levels in the cerebello-thalamo-cortical loop are significantly increased in the cerebellum and significantly decreased in the motor cortex." | 1.91 | J-difference GABA-edited MRS reveals altered cerebello-thalamo-cortical metabolism in patients with hepatic encephalopathy. ( Ahn, S; Butz, M; Füllenbach, ND; Häussinger, D; Jördens, MS; Ljimani, A; Oeltzschner, G; Schnitzler, A; Thiel, TA; Wilms, LM; Wittsack, HJ; Zöllner, HJ, 2023) |
| "Hyperammonemia is a main contributor to minimal hepatic encephalopathy (MHE) in cirrhotic patients." | 1.72 | Enhanced BDNF and TrkB Activation Enhance GABA Neurotransmission in Cerebellum in Hyperammonemia. ( Arenas, YM; Felipo, V; Llansola, M; Martínez-García, M, 2022) |
| "Patients with liver disease may develop hepatic encephalopathy (HE), with cognitive impairment and motor in-coordination." | 1.46 | Sildenafil reduces neuroinflammation in cerebellum, restores GABAergic tone, and improves motor in-coordination in rats with hepatic encephalopathy. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Fustero, S; Hernández-Rabaza, V; Ibañez-Grau, A; Llansola, M; Montoliu, C; Taoro-Gonzalez, L, 2017) |
| "Sulforaphane promotes polarization of microglia from the M1 to the M2 phenotype, reducing IL-1b and increasing IL-4, IL-10, Arg1, and YM-1 in the cerebellum." | 1.43 | Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016) |
| "The pathogenesis of hepatic encephalopathy (HE) is not fully understood yet." | 1.42 | Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. ( Baumgarten, TJ; Butz, M; Hoogenboom, N; Oeltzschner, G; Schnitzler, A; Wittsack, HJ, 2015) |
| "Hepatic encephalopathy is associated with a regional specific decrease of GABA levels in the visual cortex, while no changes were revealed for the sensorimotor cortex." | 1.42 | Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. ( Baumgarten, TJ; Butz, M; Hoogenboom, N; Oeltzschner, G; Schnitzler, A; Wittsack, HJ, 2015) |
| "Patients with hepatic encephalopathy show altered motor function, psychomotor slowing and hypokinesia." | 1.33 | Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra. ( Cauli, O; Erceg, S; Felipo, V; Llansola, M, 2006) |
| "All animals were tested three times for seizure threshold, and were then decapitated and the brains removed for analysis of the amino acids." | 1.30 | Effects of ammonia on pentylenetetrazole-induced seizure threshold. ( Arikan, K; Coskun, T; Guvener, B; Oran, O, 1999) |
| " It is, however, obvious that both in rats and mice the severity of symptoms depends not only on dose and dosing schedule of TAA, but also on strain and body weight (age)." | 1.29 | Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy. ( Grauffel, C; Knödgen, B; Sarhan, S; Seiler, N, 1993) |
| "In the patients with hepatic encephalopathy, the permeability-surface area products for phenylalanine and leucine from the blood to the brain and from the brain interstitial fluid to the intracellular compartment, the unidirectional extraction and the brain amino acid influx were similar in the two groups." | 1.29 | Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. ( Almdal, T; Knudsen, GM; Paulson, OB; Schmidt, J; Vilstrup, H, 1993) |
| "In rats with hepatic encephalopathy, the concentrations of GABA, glutamate and taurine were decreased in the cerebral cortex, the hippocampus and the striatum, whereas those of aspartate and glycine were unchanged or increased." | 1.28 | Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission. ( Ebner, J; Ferenci, P; Hörtnagl, H; Lassmann, H; Pifl, C; Roth, E; Yurdaydin, C; Zimmermann, C, 1989) |
| "The pathogenesis of hepatic encephalopathy associated with portal-systemic shunting is unknown, but theories purporting major roles for ammonia, AAAs, false neurotransmitters, and GABA have been advanced." | 1.27 | Portal-systemic encephalopathy and hepatic coma. ( Jensen, DM, 1986) |
| "in galactosamine-treated animals." | 1.27 | Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. ( Knudsen, GM; Paulson, OB; Poulsen, HE, 1988) |
| "Galactosamine-induced hepatic coma is not associated with any functionally significant changes in the molecular components of the postsynaptic dopamine receptor." | 1.27 | [Pathogenesis of hepatic encephalopathy--studies in the rabbit model of acute liver failure]. ( Ferenci, P; Jones, EA; Pappas, SC; Schafer, DF, 1984) |
| "During hepatic coma, the K+-stimulated [3H]GABA release was notably diminished in the striatum and cerebellum, whereas a significant increase was observed in the hippocampus." | 1.27 | Regional brain GABA metabolism and release during hepatic coma produced in rats chronically treated with carbon tetrachloride. ( Díaz-Muñoz, M; Tapia, R, 1988) |
| "The progressive course of hepatic encephalopathy developing in rats after massive hepatic ischemia due to hepatic artery ligation within 48 hr of a portacaval shunt was not altered by the injection of a benzodiazepine antagonist, CGS 8216, in a dose that was sufficient to reverse diazepam-induced coma quickly." | 1.27 | A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. ( Ebner, J; Ferenci, P; Rzepczynski, D; Zieve, L; Zimmermann, C, 1987) |
| "Gamma-aminobutyric acid (GABA) is a potent amino acid neurotransmitter that suppresses normal neuronal activity in the central nervous system." | 1.27 | Gamma-aminobutyric acid (GABA) production by eight common bacterial pathogens. ( Minuk, GY, 1986) |
| "CSF levels of GABA in five dogs with portosystemic encephalopathy (100 +/- 13 pmol/ml) were not significantly different from those in five control dogs (96 +/- 14 pmol/ml)." | 1.27 | Cerebrospinal fluid gamma-aminobutyric acid levels in dogs with chronic portosystemic encephalopathy. ( Farrell, GC; Maddison, JE; Stewart, P; Yau, D, 1986) |
| "The mean serum GABA level for the Reye's syndrome group (3." | 1.27 | Elevated serum gamma-aminobutyric acid levels in children with Reye's syndrome. ( Buchan, K; Minuk, GY; Sarjeant, EJ, 1985) |
| "Hepatic coma was induced in rats chronically treated with CCl4, by means of a single injection of ammonium acetate." | 1.27 | Regional brain GABA metabolism and release during hepatic coma produced in rats chronically treated with carbon tetrachloride. ( Díaz-Muñoz, M; Tapia, R, 1988) |
| "Thus, hepatic encephalopathy appears to involve partial degeneration of the gamma-aminobutyric acid-containing presynaptic nerve terminals." | 1.26 | Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. ( Baraldi, M; Zeneroli, ZL, 1982) |
| "In a rabbit model the development of hepatic encephalopathy was associated with increased levels of GABA in plasma, increased permeability of the blood-brain barrier, increased numbers of binding-sites for GABA and benzodiazepines in the brain, and a pattern of neural activity similar to that induced by drugs which activate the GABA neurotransmitter system." | 1.26 | Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. ( Jones, EA; Schafer, DF, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 61 (43.57) | 18.7374 |
| 1990's | 39 (27.86) | 18.2507 |
| 2000's | 12 (8.57) | 29.6817 |
| 2010's | 21 (15.00) | 24.3611 |
| 2020's | 7 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sancho-Alonso, M | 1 |
| Garcia-Garcia, R | 2 |
| Teruel-Martí, V | 1 |
| Llansola, M | 8 |
| Felipo, V | 8 |
| Lu, J | 1 |
| Li, Y | 2 |
| Zhang, C | 1 |
| Yang, X | 1 |
| Qiang, J | 1 |
| Arenas, YM | 1 |
| Martínez-García, M | 1 |
| Zöllner, HJ | 2 |
| Thiel, TA | 1 |
| Füllenbach, ND | 2 |
| Jördens, MS | 1 |
| Ahn, S | 1 |
| Wilms, LM | 1 |
| Ljimani, A | 1 |
| Häussinger, D | 3 |
| Butz, M | 3 |
| Wittsack, HJ | 4 |
| Schnitzler, A | 4 |
| Oeltzschner, G | 4 |
| Liu, XF | 1 |
| Lu, JJ | 1 |
| Yang, XY | 1 |
| Qiang, JW | 1 |
| Jaffe, A | 1 |
| Lim, JK | 1 |
| Jakab, SS | 1 |
| Bäckström, T | 1 |
| Das, R | 1 |
| Bixo, M | 1 |
| Baumgarten, TJ | 2 |
| Neugebauer, J | 1 |
| Kircheis, G | 2 |
| Lange, J | 1 |
| Butterworth, RF | 8 |
| Palomero-Gallagher, N | 2 |
| Zilles, K | 2 |
| Sergeeva, OA | 1 |
| Ott, P | 2 |
| Vilstrup, H | 3 |
| Savlan, I | 1 |
| Liakina, V | 1 |
| Valantinas, J | 1 |
| Montoliu, C | 3 |
| Agusti, A | 5 |
| Hernandez-Rabaza, V | 4 |
| Cabrera-Pastor, A | 4 |
| Gomez-Gimenez, B | 2 |
| Malaguarnera, M | 1 |
| Dadsetan, S | 2 |
| Belghiti, M | 1 |
| Balzano, T | 4 |
| Taoro, L | 1 |
| Parekh, PJ | 1 |
| Balart, LA | 1 |
| Hoogenboom, N | 1 |
| Taoro-Gonzalez, L | 3 |
| Gonzalez-Usano, A | 1 |
| Wickrath, F | 1 |
| Forteza, J | 1 |
| ElMlili, N | 1 |
| Ibañez-Grau, A | 1 |
| Fustero, S | 1 |
| Cauli, O | 2 |
| Rodrigo, R | 1 |
| Monfort, P | 1 |
| Piedrafita, B | 1 |
| El Mlili, N | 1 |
| Boix, J | 1 |
| García Compeán, D | 1 |
| Valadez Castillo, R | 1 |
| Barragán, RF | 1 |
| Bidmon, HJ | 1 |
| Cremer, M | 1 |
| Schleicher, A | 1 |
| Reifenberger, G | 1 |
| Kostopoulos, G | 1 |
| Harris, MK | 1 |
| Elliott, D | 1 |
| Schwendimann, RN | 1 |
| Minagar, A | 1 |
| Jaffe, SL | 1 |
| Márquez-Aguirre, AL | 1 |
| Canales-Aguirre, AA | 1 |
| Gómez-Pinedo, U | 1 |
| Gálvez-Gastélum, FJ | 1 |
| Leke, R | 1 |
| Bak, LK | 1 |
| Iversen, P | 1 |
| Sørensen, M | 1 |
| Keiding, S | 1 |
| Portela, LV | 1 |
| Schousboe, A | 1 |
| Waagepetersen, HS | 1 |
| Barbaccia, ML | 1 |
| Jones, EA | 20 |
| Mullen, KD | 3 |
| Ahboucha, S | 2 |
| Talani, G | 1 |
| Fanutza, T | 1 |
| Sanna, E | 1 |
| Biggio, G | 1 |
| Gamrani, H | 1 |
| Patel, D | 1 |
| McPhail, MJ | 1 |
| Cobbold, JF | 1 |
| Taylor-Robinson, SD | 1 |
| Cichoż-Lach, H | 1 |
| Michalak, A | 2 |
| Albrecht, J | 7 |
| Zielińska, M | 1 |
| Helewski, K | 1 |
| Kowalczyk-Ziomek, G | 1 |
| Konecki, J | 1 |
| Lu, LG | 1 |
| Erceg, S | 1 |
| Wang, L | 1 |
| Maher, TJ | 1 |
| Wurtman, RJ | 1 |
| Baraldi, M | 4 |
| Zeneroli, ML | 4 |
| Ventura, E | 2 |
| Penne, A | 1 |
| Pinelli, G | 2 |
| Ricci, P | 1 |
| Santi, M | 1 |
| Anderson, B | 1 |
| Schafer, DF | 7 |
| Raabe, WA | 1 |
| Crossley, IR | 1 |
| Wardle, EN | 1 |
| Williams, R | 2 |
| Moroni, F | 1 |
| Lombardi, G | 1 |
| Moneti, G | 1 |
| Cortesini, C | 1 |
| Ferenci, P | 8 |
| Kleinberger, G | 2 |
| Hoofnagle, JH | 1 |
| Cooper, AJ | 1 |
| Ehrlich, ME | 1 |
| Plum, F | 1 |
| Schenker, S | 1 |
| Hoyumpa, AM | 1 |
| Pappas, SC | 1 |
| Borg, J | 1 |
| Warter, JM | 1 |
| Schlienger, JL | 1 |
| Imler, M | 1 |
| Marescaux, C | 1 |
| Mack, G | 1 |
| Zeneroli, ZL | 1 |
| Wysmyk-Cybula, U | 5 |
| Iuliano, E | 1 |
| Racagni, G | 1 |
| Wilkinson, SP | 1 |
| Maddison, JE | 4 |
| Watson, WE | 1 |
| Johnston, GA | 3 |
| Yurdaydin, C | 3 |
| Basile, AS | 6 |
| Lavoie, J | 2 |
| Mousseau, DD | 1 |
| Odeh, M | 1 |
| Oja, SS | 2 |
| Saransaari, P | 2 |
| Wysmyk, U | 2 |
| Minuk, GY | 5 |
| Howard, CD | 1 |
| Seifert, CF | 1 |
| Sarhan, S | 1 |
| Knödgen, B | 1 |
| Grauffel, C | 1 |
| Seiler, N | 1 |
| Knudsen, GM | 2 |
| Schmidt, J | 1 |
| Almdal, T | 1 |
| Paulson, OB | 2 |
| Rothuizen, J | 2 |
| de Kok, Y | 1 |
| Slob, A | 1 |
| Mol, JA | 1 |
| Kato, A | 1 |
| Suzuki, K | 1 |
| Sato, S | 1 |
| Rose, C | 1 |
| Butterworth, J | 1 |
| Meyer, HP | 1 |
| Hammond, JB | 1 |
| Ahmad, F | 1 |
| Behar, KL | 1 |
| Rothman, DL | 1 |
| Petersen, KF | 1 |
| Hooten, M | 1 |
| Delaney, R | 1 |
| Petroff, OA | 1 |
| Shulman, GI | 1 |
| Navarro, V | 1 |
| Petrakis, IL | 1 |
| Charney, DS | 1 |
| Krystal, JH | 1 |
| Arikan, K | 1 |
| Coskun, T | 1 |
| Guvener, B | 1 |
| Oran, O | 1 |
| Irie, T | 1 |
| Miyamoto, E | 1 |
| Kitagawa, K | 1 |
| Maruyama, Y | 1 |
| Inoue, K | 1 |
| Inagaki, C | 1 |
| Bergasa, NV | 1 |
| Rothman, RB | 1 |
| Mukerjee, E | 1 |
| Vergalla, J | 1 |
| Mitkov, D | 1 |
| Toreva, D | 1 |
| Funovics, JM | 1 |
| Fischer, JE | 1 |
| Jellinger, K | 3 |
| Riederer, P | 3 |
| He, X | 1 |
| Luan, Y | 1 |
| Hughes, RD | 1 |
| Harrison, PM | 1 |
| Murata, Y | 1 |
| Pannell, L | 1 |
| Skolnick, P | 2 |
| Yoshida, S | 1 |
| Kakegawa, T | 1 |
| Mizote, H | 1 |
| Record, CO | 1 |
| Löscher, W | 3 |
| Kretz, FJ | 3 |
| Karavias, T | 1 |
| Dillinger, U | 3 |
| Leong, DK | 1 |
| Dodd, PR | 2 |
| Hilgier, W | 1 |
| Rafałowska, U | 2 |
| Wang, F | 1 |
| Niu, Z | 1 |
| Li, ZM | 1 |
| Thirlby, RC | 1 |
| Fenster, LF | 1 |
| Coatsworth, JJ | 1 |
| Petty, F | 1 |
| Ciu, Z | 1 |
| Gao, BL | 1 |
| Bassett, ML | 1 |
| Scholz, B | 1 |
| Fenstermacher, JD | 1 |
| Zimmermann, C | 2 |
| Pifl, C | 1 |
| Ebner, J | 2 |
| Lassmann, H | 1 |
| Roth, E | 1 |
| Hörtnagl, H | 1 |
| Levy, LJ | 2 |
| Losowsky, MS | 2 |
| Tung, LC | 1 |
| Wang, XG | 1 |
| Huang, CT | 1 |
| Farrell, GC | 2 |
| Riggio, O | 1 |
| Ariosto, F | 1 |
| Merli, M | 1 |
| Romiti, A | 1 |
| Varriale, M | 1 |
| Pinto, G | 1 |
| Pieche, U | 1 |
| Capocaccia, L | 1 |
| Zieve, L | 1 |
| Rzepczynski, D | 1 |
| Van Thiel, DH | 1 |
| Gavaler, JS | 1 |
| Tarter, R | 1 |
| Schade, RR | 1 |
| Stone, BG | 1 |
| Kienzl, E | 1 |
| Brücke, T | 1 |
| Gerok, W | 1 |
| Jensen, DM | 1 |
| Giguère, JF | 2 |
| Layrargues, GP | 1 |
| Casciarri, I | 1 |
| Germini, M | 1 |
| Cavalletti, E | 1 |
| Tofanetti, O | 1 |
| Rafalowska, U | 1 |
| Jones, DB | 1 |
| Roessle, M | 1 |
| Maynard, T | 1 |
| Myslobodsky, MS | 1 |
| Bernardini, AP | 1 |
| Fiaccadori, F | 1 |
| Sarjeant, EJ | 3 |
| Díaz-Muñoz, M | 1 |
| Tapia, R | 1 |
| Poulsen, HE | 1 |
| Lockwood, AH | 1 |
| Leek, J | 1 |
| Dabrowiecki, Z | 1 |
| Yau, D | 1 |
| Stewart, P | 1 |
| Singh, NK | 1 |
| Thapliyal, A | 1 |
| Jain, AK | 1 |
| Chansuria, JP | 1 |
| Gupta, JP | 1 |
| Srivastava, PK | 1 |
| Bode, JC | 1 |
| Schäfer, K | 1 |
| Thompson, JS | 1 |
| Schafer, GJ | 1 |
| Hodgson, PE | 1 |
| Partin, JC | 1 |
| Buchan, K | 1 |
| Winder, A | 1 |
| Burgess, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Prospective, Randomized Controlled Study to Explore the Efficacy and Safety of Fecal Microbiota Transplantation With Different Bacterial Doses in the Treatment of Recurrent Hepatic Encephalopathy[NCT05669651] | 100 participants (Anticipated) | Interventional | 2022-12-01 | Active, not recruiting | |||
| Role of Magnetic Resonance Imaging in Detection of Minimal Hepatic Encephalopathy[NCT04131205] | 40 participants (Anticipated) | Observational | 2019-06-01 | Recruiting | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
49 reviews available for gamma-aminobutyric acid and Hepatic Encephalopathy
| Article | Year |
|---|---|
Pathophysiology of Hepatic Encephalopathy.
Topics: Ammonia; Animals; Astrocytes; Diabetes Complications; gamma-Aminobutyric Acid; Gastrointestinal Micr | 2020 |
Positive GABA
Topics: Animals; Anti-Anxiety Agents; Clinical Trials, Phase II as Topic; Female; GABA-A Receptor Antagonist | 2022 |
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology.
Topics: Ammonia; Basal Ganglia; Cerebellum; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Inflamm | 2019 |
Neurotransmitter receptor alterations in hepatic encephalopathy: a review.
Topics: Acetylcholine; Adenosine; Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic | 2013 |
GABAergic transmission in hepatic encephalopathy.
Topics: Animals; Brain; GABA Antagonists; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver; Re | 2013 |
Cerebral effects of ammonia in liver disease: current hypotheses.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Diffusion; Energy Metabolism; gamma- | 2014 |
Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy.
Topics: Ammonia; Cognition; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Mangan | 2014 |
Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic Encephalopathy; Humans | 2015 |
Ammonia and Its Role in the Pathogenesis of Hepatic Encephalopathy.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Chronic Disease; gamma-Aminobutyric Acid; Glutami | 2015 |
Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic Encephalopathy; Humans; Hyperammonem | 2009 |
[Pathogenesis of portal systemic encephalopathy].
Topics: Amino Acids; Ammonia; Animals; Fatty Acids; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; | 1990 |
[Molecular aspects of hepatic encephalopathy].
Topics: Astrocytes; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic Encephalopathy; Humans; Neuron | 2010 |
Much excitement about antidepressants, DBI and c-FOS.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Diazepam Binding Inhibitor; gamma-Aminobutyric | 2011 |
Theories of the pathogenesis of hepatic encephalopathy.
Topics: Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Receptors, GABA-A; Synaptic Transm | 2012 |
Hepatic encephalopathy.
Topics: Ammonia; Benzodiazepines; Dietary Supplements; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Huma | 2012 |
Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.
Topics: Ammonia; Animals; Blood-Brain Barrier; Brain; Brain Edema; gamma-Aminobutyric Acid; Hepatic Encephal | 2013 |
Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy.
Topics: Ammonia; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Neurotransmitter Agents; | 2002 |
The role of inhibitory amino acidergic neurotransmission in hepatic encephalopathy: a critical overview.
Topics: Amino Acids; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Models, Neurological; Neural | 2002 |
[Ammonia and GABA-ergic neurotransmission in pathogenesis of hepatic encephalopathy].
Topics: Ammonia; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Neurotransmitter Agents; Receptors | 2003 |
Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint.
Topics: Animals; Benzodiazepines; Brain; GABA Modulators; gamma-Aminobutyric Acid; Hepatic Encephalopathy; H | 2004 |
Potential neural mechanisms in the pathogenesis of hepatic encephalopathy.
Topics: Amino Acids; Animals; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Hepatic Encephalopathy; Ne | 1982 |
Biochemical mechanisms of hepatic encephalopathy.
Topics: Amino Acids; Ammonia; Bile Acids and Salts; Blood-Brain Barrier; Brain; Fatty Acids; gamma-Aminobuty | 1983 |
Pathophysiology of hepatic encephalopathy.
Topics: Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Brain; Brain Edema; Evoked Potentials, Visual; F | 1984 |
The GABA hypothesis--state of the art.
Topics: Animals; GABA Modulators; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Receptors, GABA | 1994 |
The role of endogenous benzodiazepines in hepatic encephalopathy: animal studies.
Topics: Animals; Benzodiazepines; Disease Models, Animal; gamma-Aminobutyric Acid; Hepatic Encephalopathy; R | 1993 |
"Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy.
Topics: Animals; Astrocytes; Brain; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Ligands; Liver | 1993 |
Current theories on the pathogenesis of hepatic encephalopathy.
Topics: Ammonia; Animals; Brain; Brain Edema; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Hepatic | 1994 |
Endotoxin and tumor necrosis factor-alpha in the pathogenesis of hepatic encephalopathy.
Topics: Amino Acids; Ammonia; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Lipopolysacc | 1994 |
Gamma-aminobutyric acid and the liver.
Topics: Animals; Bacterial Infections; Biological Transport, Active; gamma-Aminobutyric Acid; Hepatic Enceph | 1993 |
Flumazenil in the treatment of hepatic encephalopathy.
Topics: Clinical Trials as Topic; Flumazenil; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1993 |
[Hepatic encephalopathy].
Topics: Amino Acids, Branched-Chain; Ammonia; Benzodiazepines; Diagnosis, Differential; gamma-Aminobutyric A | 1995 |
Treatment of hepatic encephalopathy in patients with cirrhosis of the liver.
Topics: Amino Acids, Branched-Chain; Ammonia; Clinical Trials as Topic; gamma-Aminobutyric Acid; Hepatic Enc | 1996 |
Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy.
Topics: Ammonia; Animals; Central Nervous System; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; M | 1997 |
The involvement of ammonia with the mechanisms that enhance GABA-ergic neurotransmission in hepatic failure.
Topics: Ammonia; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver Failure; Synaptic T | 1997 |
Hepatic encephalopathy and role of antibenzodiazepines.
Topics: Flumazenil; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Hepatic Encephal | 1998 |
Pathogenesis of hepatic encephalopathy.
Topics: Ammonia; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic Encephalopathy; Humans; Liver Failure; Rece | 2000 |
Pathophysiology of hepatic encephalopathy.
Topics: Blood-Brain Barrier; Brain; Catecholamines; Energy Metabolism; gamma-Aminobutyric Acid; Glutamates; | 1991 |
Neurochemistry of hepatic encephalopathy.
Topics: Ammonia; Benzodiazepines; Brain; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1991 |
Hepatic encephalopathy, GABA-ergic neurotransmission and benzodiazepine receptor ligands.
Topics: Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Ligands; Receptors, GABA-A; Synapt | 1990 |
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy; | 1990 |
[Advances in research on mechanisms of hepatic encephalopathy].
Topics: Amino Acids; Ammonia; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1989 |
[Gamma-aminobutyric acid (GABA) in the pathogenesis of hepatic encephalopathy].
Topics: Adult; Aged; Animals; Blood-Brain Barrier; Brain; Female; gamma-Aminobutyric Acid; Hepatic Encephalo | 1987 |
[Changes in and modulation of receptor activity in hepatic encephalopathy].
Topics: Ammonia; Animals; Aspartic Acid; Binding, Competitive; Biogenic Amines; Blood-Brain Barrier; Brain; | 1985 |
Hepatic encephalopathy: a neurochemical disorder.
Topics: Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Enterobacteriaceae; Evoked Potentials; gamma-Ami | 1986 |
Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure.
Topics: Animals; Brain Chemistry; Disease Models, Animal; Evoked Potentials, Visual; gamma-Aminobutyric Acid | 1985 |
gamma-Aminobutyric acid (GABA) and hepatic encephalopathy: testing the validity of electroencephalographic evidence of the GABA hypothesis.
Topics: Animals; Behavior; Electroencephalography; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Hemod | 1987 |
Hepatic encephalopathy: pathogenesis.
Topics: Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Fatty Acids; gamma-Aminobutyric Acid; Hepatic En | 1988 |
[Nosography and pathophysiology of hepatic encephalopathy].
Topics: Amino Acids; Ammonia; Fatty Acids, Volatile; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1986 |
Pathophysiology of chronic hepatic encephalopathy.
Topics: Amines; Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Chronic Disease; Dogs; gamma-Aminobutyri | 1985 |
91 other studies available for gamma-aminobutyric acid and Hepatic Encephalopathy
| Article | Year |
|---|---|
Hyperammonemia Enhances GABAergic Neurotransmission in Hippocampus: Underlying Mechanisms and Modulation by Extracellular cGMP.
Topics: Animals; Cyclic GMP; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Hepatic Encep | 2022 |
Metabolic changes of the reduction of manganese intake in the hepatic encephalopathy rat: NMR- and MS-based metabolomics study.
Topics: Amino Acids; Ammonia; Animals; gamma-Aminobutyric Acid; Glutamate-Ammonia Ligase; Hepatic Encephalop | 2022 |
Enhanced BDNF and TrkB Activation Enhance GABA Neurotransmission in Cerebellum in Hyperammonemia.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebellum; Chlorides; gamma-Aminobutyric Acid; Hepatic | 2022 |
J-difference GABA-edited MRS reveals altered cerebello-thalamo-cortical metabolism in patients with hepatic encephalopathy.
Topics: Ammonia; Cerebellum; Choline; gamma-Aminobutyric Acid; Glutamine; Hepatic Encephalopathy; Humans; In | 2023 |
The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study.
Topics: Alanine; Ammonia; Animals; Arginine; Brain; Citrulline; gamma-Aminobutyric Acid; Glutamic Acid; Glut | 2023 |
Connecting occipital alpha band peak frequency, visual temporal resolution, and occipital GABA levels in healthy participants and hepatic encephalopathy patients.
Topics: Aged; Alpha Rhythm; Female; gamma-Aminobutyric Acid; Healthy Volunteers; Hepatic Encephalopathy; Hum | 2018 |
Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes.
Topics: Ammonia; Brain Chemistry; Creatine; Female; Flicker Fusion; gamma-Aminobutyric Acid; Glutamine; Glyc | 2015 |
Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Cell Membrane; Cerebellum; Disease Models, Ani | 2016 |
Use of quantitative brain water imaging as concentration reference for J-edited MR spectroscopy of GABA.
Topics: Body Water; Brain; Evaluation Studies as Topic; Female; gamma-Aminobutyric Acid; Hepatic Encephalopa | 2016 |
Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy.
Topics: Animals; Anti-Inflammatory Agents; Cerebellum; Cyclic GMP; Cytokines; Dinoprostone; Disease Models, | 2016 |
Sildenafil reduces neuroinflammation in cerebellum, restores GABAergic tone, and improves motor in-coordination in rats with hepatic encephalopathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Cerebellum; Disease Models, Animal; GA | 2017 |
Neurotransmitter receptor imbalances in motor cortex and basal ganglia in hepatic encephalopathy.
Topics: Acetylcholine; Adenosine; Adult; Aged; Autoradiography; Basal Ganglia; Binding Sites; Case-Control S | 2009 |
Neurologic presentations of hepatic disease.
Topics: Ammonia; Animals; Brain; Diagnosis, Differential; gamma-Aminobutyric Acid; Hepatic Encephalopathy; H | 2010 |
Synthesis of neurotransmitter GABA via the neuronal tricarboxylic acid cycle is elevated in rats with liver cirrhosis consistent with a high GABAergic tone in chronic hepatic encephalopathy.
Topics: Acetates; Ammonia; Animals; Astrocytes; Brain Chemistry; Chromatography, High Pressure Liquid; Chron | 2011 |
Reduced brain levels of DHEAS in hepatic coma patients: significance for increased GABAergic tone in hepatic encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Coma; Dehydroepiandrosterone Sulfate; Female; gamma-Aminobu | 2012 |
[Pathogenesis of hepatic encephalopathy].
Topics: Amino Acids; Ammonia; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 2004 |
Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra.
Topics: Animals; Basal Ganglia; Chromones; Chronic Disease; GABA Antagonists; gamma-Aminobutyric Acid; Gluta | 2006 |
Oral L-glutamine increases GABA levels in striatal tissue and extracellular fluid.
Topics: Administration, Oral; Animals; Corpus Striatum; Extracellular Fluid; gamma-Aminobutyric Acid; Glutam | 2007 |
Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist.
Topics: Animals; Benzodiazepines; Brain; Diazepam; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Hepat | 1984 |
A proposed therapy for the encephalopathies of Reye's syndrome and hepatic encephalopathy.
Topics: Animals; Benzodiazepines; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Rabbits; Receptor | 1984 |
Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system.
Topics: 4-Aminobutyrate Transaminase; Animals; Barbiturates; Benzodiazepines; Blood-Brain Barrier; Disease M | 1982 |
Hepatic encephalopathy and GABA.
Topics: Ammonia; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Neural Inhibition | 1982 |
The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy.
Topics: Acetates; Animals; Cerebral Cortex; Disease Models, Animal; gamma-Aminobutyric Acid; Glucose; Glutam | 1983 |
Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease.
Topics: Adult; Animals; gamma-Aminobutyric Acid; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Hepati | 1983 |
The enigma of hepatic encephalopathy.
Topics: Adult; Ammonia; Animals; Child; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Hepatic Encephal | 1983 |
Hepatic encephalopathy today.
Topics: Brain; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver | 1984 |
Hepatic encephalopathy: GABA or ammonia?
Topics: Ammonia; Animals; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver | 1984 |
[Pathogenesis of hepatic encephalopathy--studies in the rabbit model of acute liver failure].
Topics: Ammonia; Animals; Arousal; Brain; Disease Models, Animal; Electroencephalography; Evoked Potentials, | 1984 |
Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy.
Topics: 5-Hydroxytryptophan; Blood-Brain Barrier; Catecholamines; gamma-Aminobutyric Acid; Hepatic Encephalo | 1982 |
Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid.
Topics: Bicuculline; Binding, Competitive; Brain; Disease Models, Animal; Galactosamine; gamma-Aminobutyric | 1982 |
[Gamma-aminobutyric acid (GABA) metabolism in the rat brain in experimental hepatic encephalopathy induced by carbon tetrachloride].
Topics: Animals; Brain; Carbon Tetrachloride Poisoning; Female; gamma-Aminobutyric Acid; Hepatic Encephalopa | 1984 |
[Gamma-aminobutyric acid (GABA) metabolism in the rat brain in experimental hepatic encephalopathy].
Topics: Animals; Brain; Female; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Male; Rats; Rats, Inbred St | 1983 |
[Gamma-aminobutyric acid (GABA) content of the rat brain in experimental hepatic encephalopathy].
Topics: Animals; Cerebral Cortex; Corpus Striatum; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Male; Ra | 1983 |
Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats.
Topics: Animals; Brain; Galactosamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hepatic Encephalopa | 1982 |
GABA, benzodiazepines and hepatic encephalopathy.
Topics: Benzodiazepines; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1995 |
L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy.
Topics: Ammonia; Animals; Cerebral Cortex; Chronic Disease; Dogs; gamma-Aminobutyric Acid; Glutamic Acid; He | 1995 |
Loss of GABAB binding sites in the cerebral cortex of rats with acute hepatic encephalopathy.
Topics: Acute Disease; Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Hepatic Encephalopathy; In Vitro T | 1993 |
Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy.
Topics: Amino Acids; Animals; Behavior, Animal; Brain; Citrulline; gamma-Aminobutyric Acid; Hepatic Encephal | 1993 |
Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy.
Topics: Adult; Amino Acids; Blood Glucose; Blood-Brain Barrier; Carbon Dioxide; Extracellular Space; Female; | 1993 |
GABAergic inhibition of the pituitary release of adrenocorticotropin and alpha-melanotropin is impaired in dogs with hepatic encephalopathy.
Topics: Adrenocorticotropic Hormone; Animals; Bicuculline; Cells, Cultured; Creatinine; Dog Diseases; Dogs; | 1996 |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure.
Topics: Animals; Aspartic Acid; Brain Chemistry; Excitatory Amino Acids; Extracellular Space; gamma-Aminobut | 1996 |
Modulation of the GABAergic tone by benzodiazepine receptor ligands in chronic hepatic encephalopathy in the dog.
Topics: Animals; Benzodiazepines; Dog Diseases; Dogs; Electroencephalography; Female; gamma-Aminobutyric Aci | 1998 |
Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients.
Topics: Adult; Age of Onset; Alcoholism; Carnosine; Cerebral Cortex; gamma-Aminobutyric Acid; Hepatic Enceph | 1999 |
Effects of ammonia on pentylenetetrazole-induced seizure threshold.
Topics: Ammonia; Animals; Aspartic Acid; Brain; Dose-Response Relationship, Drug; Drug Interactions; gamma-A | 1999 |
An anxiolytic agent, dihydrohonokiol-B, inhibits ammonia-induced increases in the intracellular Cl(-) of cultured rat hippocampal neurons via GABA(c) receptors.
Topics: Ammonia; Ammonium Chloride; Animals; Anti-Anxiety Agents; Biphenyl Compounds; Chlorides; Dose-Respon | 2001 |
Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure.
Topics: Animals; Brain; Cell Membrane; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; gamma-Aminobutyric Acid; Hepatic | 2002 |
A study on the comatose action of short chain fatty acids.
Topics: Animals; Brain Chemistry; Coma; Fatty Acids; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Rats | 1979 |
Brain energy metabolism and alterations of transmitter profiles in acute hepatic coma.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Ammonia; Animals; Brain; Ene | 1978 |
Brain monoamines in metabolic coma and stroke.
Topics: Acute Disease; Aged; Biogenic Amines; Brain Chemistry; Coma; Diabetic Coma; Dopamine; Female; gamma- | 1978 |
[Study on variation of plasma gamma-aminobutyric acid concentration in rat model of hepatic encephalopathy due to fulminant hepatic failure].
Topics: Animals; Galactosamine; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Male; Rats; Rats, Inbred St | 1992 |
Enhanced GABA release in cerebral cortical slices derived from rats with thioacetamide-induced hepatic encephalopathy.
Topics: Ammonium Chloride; Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Kineti | 1992 |
Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.
Topics: Adult; Aged; Benzodiazepines; Brain Chemistry; Chromatography; Diazepam; Flumazenil; Frontal Lobe; g | 1991 |
Benzodiazepine receptor ligands and hepatic encephalopathy: further unfolding of the GABA story.
Topics: Animals; Azides; Benzodiazepines; Benzodiazepinones; Brain; Central Nervous System; Flumazenil; gamm | 1991 |
[Oral supplementation of branched-chain amino acids in patients with hepatic failure].
Topics: Amino Acids, Branched-Chain; Enteral Nutrition; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Hum | 1991 |
Marked increases of plasma gamma-aminobutyric acid concentrations in cirrhotic patients with portacaval shunts are not associated with alterations of cerebral functions.
Topics: Electroencephalography; Esophageal and Gastric Varices; Female; gamma-Aminobutyric Acid; Gastrointes | 1991 |
[The blood level of gamma-aminobutyric acid in patients with liver cirrhosis and portacaval anastomosis].
Topics: gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Portacaval Shunt, Surgical | 1991 |
Plasma GABA-like activity in rats with hepatic encephalopathy is due to GABA and taurine.
Topics: Animals; Binding, Competitive; Chromatography, High Pressure Liquid; gamma-Aminobutyric Acid; Glutam | 1990 |
Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response?
Topics: Acetamides; Animals; Arginine; Brain; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; He | 1990 |
Plasma gamma-aminobutyric acid in experimental fulminant hepatic failure of rats and its diagnostic value in hepatic encephalopathy.
Topics: Alanine Transaminase; Animals; Chemical and Drug Induced Liver Injury; Galactosamine; gamma-Aminobut | 1990 |
Reversal of chronic hepatic encephalopathy by colonic exclusion: poor correlation with blood GABA levels.
Topics: Ammonia; Chronic Disease; Electroencephalography; Female; gamma-Aminobutyric Acid; Hepatic Encephalo | 1990 |
Increased brain uptake of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy.
Topics: Animals; Brain; Butanols; Carbon Radioisotopes; Disease Models, Animal; Galactosamine; gamma-Aminobu | 1990 |
[Hepatic encephalopathy].
Topics: Amino Acids; Ammonia; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Neurotoxins; Neurotra | 1986 |
Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission.
Topics: Acetamides; Animals; Brain; Chemical and Drug Induced Liver Injury; gamma-Aminobutyric Acid; Glutama | 1989 |
Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease.
Topics: Acute Disease; Adult; Chronic Disease; Delta Rhythm; Female; gamma-Aminobutyric Acid; Hepatic Enceph | 1989 |
Reduction of highly elevated plasma levels of gamma-aminobutyric acid does not reverse hepatic coma.
Topics: Adult; Animals; Cross Circulation; Female; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; | 1989 |
Brain gamma-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma-aminobutyric acid-like activity.
Topics: Animals; Binding Sites; Brain; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Male; Radioligand As | 1987 |
Changes in cerebral receptors for gamma aminobutyric acid in patients with hepatic encephalopathy.
Topics: Aged; Aged, 80 and over; Brain; Coronary Disease; Female; gamma-Aminobutyric Acid; Hepatic Encephalo | 1988 |
A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding.
Topics: Animals; Benzodiazepines; Brain; Diazepam; gamma-Aminobutyric Acid; Hepatic Artery; Hepatic Encephal | 1987 |
Hepatic encephalopathy and the neural regulation of hypothalamic pituitary function.
Topics: Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Brain; Catecholamines; Fatty Acids; gamma-Aminob | 1985 |
[Metabolic principles in hepatic encephalopathy].
Topics: Amino Acids; Ammonia; Blood-Brain Barrier; Brain; Evoked Potentials, Visual; Fatty Acids; gamma-Amin | 1985 |
Portal-systemic encephalopathy and hepatic coma.
Topics: Amino Acids; Ammonia; Dietary Proteins; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Lac | 1986 |
Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.
Topics: Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Chromatography, High Pressure Liquid; Female; gam | 1987 |
Opiate receptors and beta-endorphin levels in brain areas of dogs with portal-systemic encephalopathy.
Topics: Animals; beta-Endorphin; Brain; Cerebral Cortex; Dogs; Endorphins; Female; gamma-Aminobutyric Acid; | 1985 |
Na+/K+-ATPase activity and GABA uptake in astroglial cell-enriched fractions and synaptosomes derived from rats in the early stage of experimental hepatogenic encephalopathy.
Topics: Animals; Astrocytes; gamma-Aminobutyric Acid; Hepatic Encephalopathy; In Vitro Techniques; Rats; Rat | 1985 |
Hepatic encephalopathy. Application of visual evoked responses to test hypotheses of its pathogenesis in rats.
Topics: Ammonia; Animals; Caprylates; Disulfides; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Hepati | 1987 |
The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes.
Topics: Animals; Common Bile Duct; Disaccharides; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Homeostas | 1988 |
Regional brain GABA metabolism and release during hepatic coma produced in rats chronically treated with carbon tetrachloride.
Topics: 4-Aminobutyrate Transaminase; Animals; Brain; Carbon Tetrachloride; gamma-Aminobutyric Acid; Glutama | 1988 |
Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport.
Topics: Animals; Blood-Brain Barrier; Galactosamine; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Male; | 1988 |
Cerebral aminoacids in portal-systemic encephalopathy: lack of evidence for altered gamma-aminobutyric acid (GABA) function.
Topics: Amino Acids; Ammonia; Animals; Brain Stem; Cerebral Cortex; gamma-Aminobutyric Acid; Glutamate Decar | 1986 |
Enhanced potassium-stimulated gamma-aminobutyric acid release by astrocytes derived from rats with early hepatogenic encephalopathy.
Topics: Animals; Astrocytes; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Potassium; Rats | 1987 |
Metabolic encephalopathies: opportunities and challenges.
Topics: Ammonia; Animals; Brain; Brain Diseases; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Me | 1987 |
Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy.
Topics: Chromatography, Gas; GABA Antagonists; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Live | 1987 |
Changes in the metabolism and binding of GABA in the rat brain in thioacetamide-induced hepatogenic encephalopathy.
Topics: 4-Aminobutyrate Transaminase; Acetamides; Animals; Brain; Cerebral Cortex; Corpus Striatum; Female; | 1986 |
Gamma-aminobutyric acid (GABA) production by eight common bacterial pathogens.
Topics: Bacteria; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1986 |
Cerebrospinal fluid gamma-aminobutyric acid levels in dogs with chronic portosystemic encephalopathy.
Topics: Ammonia; Animals; Dogs; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Tryptophan | 1986 |
Alterations in plasma and CSF levels of GABA, 5-HT and amino acids in fulminant hepatic failure.
Topics: Adolescent; Adult; Amino Acids, Branched-Chain; Child; Female; gamma-Aminobutyric Acid; Hepatic Ence | 1985 |
Hepatic encephalopathy.
Topics: Ammonia; Brain; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1986 |
gamma-Aminobutyric acid plasma levels and brain binding in Eck fistula dogs.
Topics: Animals; Brain; Dogs; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Portacaval Shunt, Surgical | 1985 |
Acute hepatic failure in children.
Topics: Acute Disease; Blood-Brain Barrier; Child; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; | 1985 |
Elevated serum gamma-aminobutyric acid levels in children with Reye's syndrome.
Topics: Child; Child, Preschool; Female; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Hepatitis A; Hepat | 1985 |
Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.
Topics: Ammonia; Chronic Disease; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Kidney Failure, C | 1985 |